دورية أكاديمية
Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment.
| العنوان: | Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment. |
|---|---|
| المؤلفون: | Kostik MM; Saint-Petersburg State Paediatric Medical University, Saint-Petersburg, Russia. kost-mikhail@yandex.ru, mikhail.kostik@gmail.com., Isupova EA; Saint-Petersburg State Paediatric Medical University, Saint-Petersburg, Russia., Chikova IA; Saint-Petersburg State Paediatric Medical University, Saint-Petersburg, Russia., Dubko MF; Saint-Petersburg State Paediatric Medical University, Saint-Petersburg, Russia., Masalova VV; Saint-Petersburg State Paediatric Medical University, Saint-Petersburg, Russia., Snegireva LS; Saint-Petersburg State Paediatric Medical University, Saint-Petersburg, Russia., Kalashnikova OV; Saint-Petersburg State Paediatric Medical University, Saint-Petersburg, Russia., Chasnyk VG; Saint-Petersburg State Paediatric Medical University, Saint-Petersburg, Russia. |
| المصدر: | Clinical and experimental rheumatology [Clin Exp Rheumatol] 2018 Mar-Apr; Vol. 36 (2), pp. 335-341. Date of Electronic Publication: 2017 Dec 15. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Pisa : Clinical And Experimental Rheumatology S.A.S Original Publication: Pisa, Italy : Pacini editore, [1983- |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized/*therapeutic use , Arthritis, Juvenile/*drug therapy, Antibodies/blood ; Antibodies, Monoclonal, Humanized/immunology ; Child ; Child, Preschool ; Female ; Humans ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/physiology ; Male ; Proportional Hazards Models ; Retrospective Studies |
| مستخلص: | Objectives: The aim of our study was to evaluate disease courses and outcomes of sJIA children undergoing tocilizumab (TCZ) treatment, and to establish the predictors which distinguish inactive disease and disease flares. Methods: Our retrospective study included 48 active sJIA children who were refractory to different anti-rheumatic drugs and who were then started on TCZ. The effectiveness of TCZ was assessed by the changes of sJIA attributed signs and symptoms and the remission was judged according to the Wallace (2004) criteria. Results: The main demographic parameters (Me; IQR) were shown; mean age: 9.9 (5-12.7) years and mean duration of TCZ administration: 27.0 (5.9-89.7) months. During the TCZ treatment 40 cases (83.3%) achieved remission in 138.5 (56.0; 255.0) days. Patients who achieved remission had milder disease course, and presented less frequent epatosplenomegaly, lung, heart involvement and MAS. They had higher Hb and lower WBC, granulocytes, ESR, CRP, LDH, ferritin. The main predictors of achievement of inactive disease, calculated with Cox-regression models, were CRP≤82.0 mg/l (OR=7.9, HR=1.17), ESR≤32 mm/h (OR=17.0, HR=0.85), ferritin ≤273 ng/ml (OR=56.5, HR=2.6), Hb>113 g/l (OR=17.0, HR=1.33), LDH≤676 U/l (OR=113.6, HR=3.2), PLT>335*109/l (OR=5.0, HR=2.5), and intensive depression of WBC in 2 weeks after the 1st TCZ infusion>11% (OR=13.0, HR=6.0) and granulocytes>12% (OR=14.0, HR=4.7). Conclusions: sJIA children with milder disease course have more posssibilty of achieving disease remission during TCZ treatment. Male sex, signs of high disease activity, previous CS treatment, the long time needed to achieve inactive disease and treatment protocol deviations increased the risk of sJIA flare. |
| المشرفين على المادة: | 0 (Antibodies) 0 (Antibodies, Monoclonal, Humanized) 0 (Interleukin-6) I031V2H011 (tocilizumab) |
| تواريخ الأحداث: | Date Created: 20180106 Date Completed: 20180614 Latest Revision: 20180614 |
| رمز التحديث: | 20221213 |
| PMID: | 29303703 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0392-856X |
|---|